COVID-19 Business Intelligence and Analysis for Clinical Laboratories, Pathology Groups and Hospital Administration
Reliable COVID-19 Business Intelligence and analysis for clinical laboratories, pathology groups and Laboratory Diagnostics.
Recent developments in emergency use authorizations for investigational therapies for use in the treatment of mild to moderate COVID-19.
Points of interest from the US Food and Drug Administration’s November 2020 update to investigational COVID-19 convalescent plasma guidelines.
More about the first at-home COVID-19 test, a rapid, single-use molecular diagnostic test kit for the qualitative detection of SARS-CoV-2 RNA from self-collected nasal swab specimens.
Tests of interest as part of new FDA-allowed at-home specimen collection options.
Breakout of examples of modifications that will and will not be permitted with influenza and RSV clinical lab tests during the public health emergency.
With over 50 COVID-19 antibody tests authorized for use under FDA EUA, a milestone has been recognized with the FDA’s Nov. 6, 2020, announcement.
Key update and recommendations released Oct. 26, 2020, that affect SARS-CoV-2 antigen test use.
October 2020 Medicare loan repayment update for providers.
New FDA update to comparative COVID-19 test performance data now includes information about most available SARS-CoV-2 diagnostic molecular tests.
Interim final rule (CMS-3401-IFC) from CMS mandates daily reporting for broader surveillance of COVID-19 and influenza statistics, and outlines strict enforcement mechanisms.
Rollout and availability of rapid SARS-CoV-2 antigen tests opens wave of CLIA certification issues triggering CMS cease and desist letters.
Three teaching points for self-collecting SARS-CoV-2, COVID-19 specimens; FDA cautions healthcare providers about poor specimen quality.
Quick links to clarification of CMS policy for clinical laboratories and updated FDA recommendations to healthcare providers about antigen testing of certain asymptomatic individuals.
A six-point primer to the new CMS clinical laboratory CLIA quick start guide released in September 2020.
With 47 COVID-19 antibody tests authorized for use under FDA EUA as of Sept. 24, 2020, only one is authorized as POC for fingerstick blood samples collected in patient care settings.
Lowest limit of detection noted.
Three essential points pertaining to university laboratories planning for SARS-CoV-2 surveillance testing.
Guidance released Sept. 8 provides simplified details on nursing home testing that should be performed, also identifies three circumstances related to COVID-19 testing triggers.
Four key points from the FDA’s September 2020 update to initial COVID-19 convalescent plasma guidelines.
Combination coronavirus flu tests readying for flu season.
Details fall into place for invoking the Defense Production Act for SARS-CoV-2 antigen test production.
Points of interest from CMS-3401-IFC and CLIA requirements modified in August 2020.
New guidance for those seeking approval or clearance of, or an EUA for, an LDT, and for those opting to use LDTs in their laboratories without FDA premarket review or authorization.
The four companies implicated in recent FDA warning letters over unauthorized COVID-19 tests. What did these tests have in common?
Update on emergency use authorization for third SARS-CoV-2 POC antigen test.
What the National Cancer Institute (NCI) found toward the revocation of Autobio Diagnostics’ antibody test EUA.
New developments in measuring SARS-CoV-2 antibodies.
Overview of new CMS resource for understanding SARS-CoV-2 antigen test distribution to nursing homes.
FDA guidance provides pathway for developers and manufacturers to obtain EUAs for at-home and over-the-counter COVID-19 testing. The US Food and Drug Administration (FDA) issued
New EUA opens the door for increased availability of COVID-19 testing for asymptomatic individuals.
The FDA recently updated its interactive tool designed to assist in identifying COVID-19 testing supply alternatives.
Shipping guidelines for SARS-CoV-2 specimens emphasized as many clinical laboratories are not shipping specimens correctly.
Pooled SARS-CoV-2 diagnostic testing is now available after FDA issues first EUA for this testing method.
A look at new COVID-19 test data reporting requirements for in-house clinical laboratories of critical access hospitals, children’s hospitals, general hospitals (including acute, trauma, and teaching hospitals), long-term acute care hospitals, military hospitals, oncology hospitals, orthopedic hospitals, pediatric long-term acute care hospitals, psychiatric hospitals, rehabilitation hospitals, surgical hospitals, Veterans Administration hospitals, women’s hospitals, and women’s and children’s hospitals, according to HHS.
Overview of detection detailed in combination SARS-CoV-2 and flu testing EUAs.
Interest is increasing in pooled sampling for SARS-CoV-2 surveillance testing. CMS addressed three primary questions in a recent FAQ.
Five points of interest to clinical laboratory leaders, gleaned from an over 8,000-word payer guidance document jointly developed by federal agencies.
This point-of-care test can potentially scale up to test millions, according to FDA Commissioner Stephen Hahn, MD.
Explanation of warnings issued to KBMO Diagnostics related to at-home COVID-19 testing.
Where to start when working on a laboratory developed test using next generation sequencing (NGS) technology for diagnosing SARS-CoV-2, according to Timothy Stenzel, MD, PhD.
Selected quotes from Jeffrey Shuren, MD, JD, Director of the Center for Devices and Radiological Health at the FDA on the June 16, 2020, updates to EUA templates.
Four important statements from a June 8 CDC clinical laboratory call covering COVID-19 test data reporting requirements.
As of June 12, 2020, the FDA had authorized 135 COVID-19 tests under emergency use authorization (EUA), which include 114 molecular tests, 20 antibody tests, and 1 antigen test. The FDA has also released a new interactive tool designed to assist in identifying COVID-19 testing supply deficiencies and alternatives.
The FDA addresses concerns of unreliable tests by providing a new tool to support their evaluation of SARS-CoV-2 diagnostic tests.
SARS-CoV-2 test reporting requirements just multiplied. Clinical laboratories are on a deadline now.
Introduction to commercially manufactured SARS-CoV-2 serology tests listed with the status of “Removed – Should Not Be Distributed.”
While not specifically addressed by CMS, the U.S. Department of Health and Human Services (HHS) may fine non-compliant institutions up to $300 per day.
Multiple-step methods versus single-step methods differentiated.
As the number of COVID-19 cases in the United States has increased, the availability of real COVID-19 positive specimens has also increased.
Segmented highlights from interim final rule CMS-5531-IFC, which was released with a 60-day comment period, effective May 8, 2020. Recent changes are intended to increase the COVID-19 response capabilities of providers and hospitals.
Major highlights of the FDA’s revised COVID-19 testing policy issued May 11, 2020.
Compare SARS-CoV-2 testing requirements for clinical laboratories and other facilities based on new 20-06-CLIA memo issued April 30, 2020.
Clinical laboratory directors may reduce their risk of fraud and waste by familiarizing themselves with these four areas of recent focus.
Impact of relaxing HIPAA enforcement during COVID-19 pandemic.
Recent developments in emergency use authorizations for investigational therapies for use in the treatment of mild to moderate COVID-19.
Points of interest from the US Food and Drug Administration’s November 2020 update to investigational COVID-19 convalescent plasma guidelines.
More about the first at-home COVID-19 test, a rapid, single-use molecular diagnostic test kit for the qualitative detection of SARS-CoV-2 RNA from self-collected nasal swab specimens.
Tests of interest as part of new FDA-allowed at-home specimen collection options.
Breakout of examples of modifications that will and will not be permitted with influenza and RSV clinical lab tests during the public health emergency.
With over 50 COVID-19 antibody tests authorized for use under FDA EUA, a milestone has been recognized with the FDA’s Nov. 6, 2020, announcement.
Recent developments in emergency use authorizations for investigational therapies for use in the treatment of mild to moderate COVID-19.
Points of interest from the US Food and Drug Administration’s November 2020 update to investigational COVID-19 convalescent plasma guidelines.
More about the first at-home COVID-19 test, a rapid, single-use molecular diagnostic test kit for the qualitative detection of SARS-CoV-2 RNA from self-collected nasal swab specimens.
Tests of interest as part of new FDA-allowed at-home specimen collection options.
Breakout of examples of modifications that will and will not be permitted with influenza and RSV clinical lab tests during the public health emergency.
With over 50 COVID-19 antibody tests authorized for use under FDA EUA, a milestone has been recognized with the FDA’s Nov. 6, 2020, announcement.
Dear Colleague,
In these challenging times for our colleagues in clinical laboratories, pathology practices and hospital administration, The Dark Intelligence Group (TDIG) — through generous grants from our partners — is bringing you the COVID-19 STAT Intelligence Briefings.
We’ve added analysts, writers and skilled editors to the COVID-19 STAT team to uncover, analyze, and immediately report to you what’s happening with the SARS-CoV-2 pandemic, packaged with the insights you need to deliver quality testing for patient care and keep your lab’s financial ship afloat. As part of our mission, we are also bringing you real-time data from our partners around testing that you will not find anywhere else.
Please let me know how we can better improve this service to fit your needs. If you would like to offer a grant to keep our mission going with this site, please contact me at rmichel@darkreport.com.
Sincerely,
Robert L. Michel
President, Founder
The Dark Intelligence Group
